JW Therapeutics acquires Syracuse and license to Eureka’s solid tumour technology in China

This article was originally published here

Terms of the transaction were not disclosed. Dr. Cheng Liu, Founder and President of Eureka Therapeutics, will join the Board of Directors of JW Therapeutics, and Victor Shum,

The post JW Therapeutics acquires Syracuse and license to Eureka’s solid tumour technology in China appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply